logo

For the Inventor, By the Inventor

Jersey City, NJ, United States of America

Scynexis, Inc.


USPTO Granted Patents = 19

% Expired Patents = 42.1



Trademarks = 3

Forward Citations = 51

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal David Renwick Houck (8 out of 8 patents)

silverMedal Michael Robert Peel (4 out of 8 patents)

bronzeMedal Yi Zhang (3 out of 16 patents)

4.  David A Angulo Gonzalez (3 out of 3 patents)

5.  Keqiang Li (3 out of 5 patents)

6.  Ahmed Mamai (3 out of 5 patents)

7.  Andrew Scribner (2 out of 12 patents)

8.  Weiming Fan (2 out of 9 patents)

9.  Hans Georg Fliri (2 out of 2 patents)

10.  James M Balkovec (2 out of 47 patents)

11.  Frances A Bouffard (2 out of 18 patents)

12.  Phieng Siliphaivanh (1 out of 35 patents)

13.  Rebecca A Chmielowski (1 out of 2 patents)

14.  Hao Liu (1 out of 3 patents)

15.  Dongfang Meng (1 out of 23 patents)


19 patents:

1. 12594266 - Triterpenoid antifungals for the treatment or prevention ofspp. pneumonia (2026-04-07),
2. 11534433 - Antifungal agents with enhanced activity in acidic pH (2022-12-27),
3. 11110102 - Antifungal agents used in combination (2021-09-07),
4. 10927142 - Salts and polymorphs of SCY-078 (2021-02-23),
5. 10370406 - Salts and polymorphs of SCY-078 (2019-08-06),
6. 10174074 - Salts and polymorphs of SCY-078 (2019-01-08),
7. 9090671 - Macrocyclic peptides (2015-07-28),
8. 8674087 - Processes for isolation and purification of enfumafungin (2014-03-18),
9. 8551952 - Methods for the treatment and prevention of ocular disorders (2013-10-08),
10. 8536114 - Macrocycles (2013-09-17),
11. 8329658 - Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection (2012-12-11),
12. 8222255 - Antifungal agents (2012-07-17),
13. 8188052 - Method for the treatment and prevention of ocular disorders (2012-05-29),
14. 7863465 - Antifungal agents (2011-01-04),
15. 7754685 - Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection (2010-07-13),
Company Overview
Scynexis, Inc. is a biopharmaceutical company based in Jersey City, NJ, focused on developing innovative therapies for difficult-to-treat infections. The company specializes in antifungal drug development, aiming to address unmet medical needs in the field of infectious diseases. Scynexis leverages advanced research methodologies and a commitment to scientific excellence to create effective treatment options, enhancing patient outcomes and contributing to the global fight against fungal infections.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Scynexis, Inc. USPTO Patent Assignee Logo
19 Patents

#12 in Jersey City, NJ

#647 in New Jersey

#17,138 in US

#32,663 in the World

Jersey City, NJ (US)
Jersey City, NJ, United States of America

Scynexis, Inc.

Forward Citations = 51

28 inventors:

goldMedal David Renwick Houck (8 out of 8 patents)

silverMedal Michael Robert Peel (4 out of 8 patents)

bronzeMedal Yi Zhang (3 out of 16 patents)

4.  David A Angulo Gonzalez (3 out of 3 patents)

5.  Keqiang Li (3 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Scynexis, Inc.. Retrieved from https://idiyas.com/company/scynexis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…